in tumor endothelium revealed 81 genes whose expression was decreased in tumor endothelial cells compared with quiescent endothelial cells and that were reexpressed after treatment with the DNA methylation inhibitor 5-aza-2 ′ -deoxycytidine (DAC) and the histone deacetylase inhibitor trichostatin A. Silencing of these genes in tumor endothelium was associated with modifications of histones in the promoter regions but not with promoter CpG island methylation ( 1 ) . It is interesting that 21 (26%) of the 81 genes were reported to be hypermethylated at their promoters and silenced in various tumor types, suggesting that expression of those genes in tumor cells may be regulated by promoter methylation ( 1 ) .
One of the identifi ed genes was N-Myc downstream-regulated gene 4 ( NDRG4 ; also known as SMAP-8 and BDM1 ). The protein encoded by this gene, NDRG4, is a member of the NDRG protein family, which comprises four members named NDRG1 -4 that have 57% -65% amino acid sequence homology ( 2 , 3 ) . NDRG1 is the most extensively studied member of the NDRG family. Expression of NDRG1 is decreased in cancer cells ( 4 -9 ) but increases in cancer cells that are treated with DAC ( 5 , 6 ) . It has been demonstrated that NDRG1 overexpression in colorectal cancer cell lines reduces their ability to metastasize in nude mice, and the NDRG1-mediated suppression of metastasis is thought to involve the induction of colorectal cancer cell differentiation and a partial reversal of the metastatic phenotype ( 6 ) . NDRG2 has been described as a candidate tumor suppressor gene ( 10 , 11 ) and displays promoter CpG island methylation in meningiomas ( 10 ) and in breast, liver, and lung cancer cell lines ( 12 ) . To our knowledge, the roles of NDRG3 and NDRG4 in cancer have not been addressed.
The NDRG4 gene is located at chromosome 16q21 -q22.3, spans 26 kilobases, and contains 17 exons that include the entire sequence of the three complementary DNA (cDNA) isoforms:
NDRG4-B , NDRG4-B var
, and NDRG4-H ( 2 ). To our knowledge, NDRG4 expression has only been described in the brain and heart using northern blot analysis. The molecular characterization of NDRG4 and the role of this protein in the nervous system have been investigated mainly in the rat ( 13 -16 ) , where it is thought to participate in processes that lead to cellular differentiation and neurite formation ( 14 ) .
Here we examined the expression of NDRG4 at the mRNA and protein levels in normal human colon mucosa and human colorectal cancer tissue. In addition, we examined the mechanism underlying the decreased expression of NDRG4 in colorectal cancer and investigated a possible tumor suppressor function of NDRG4 by measuring colony formation and cell proliferation, migration, and invasion in colorectal cancer cell lines that stably overexpressed NDRG4 . Finally, we investigated the potential utility of NDRG4 promoter methylation as a biomarker for early detection of colorectal cancer in stool.
Materials and Methods

Study Population and Tissue Samples
NDRG4 promoter methylation was investigated in two independent well-characterized tissue series from colorectal carcinoma patients, adenoma patients, and control subjects without cancer. The first hospital-based series consisted of formalin-fixed, paraffinembedded colorectal cancer tissues (n = 90) from patients who were older than 50 years at colorectal cancer diagnosis during 1995 -2003 and were retrospectively retrieved from the tissue archive of the Department of Pathology of the Maastricht University Medical Center. We also retrieved noncancerous healthy colon mucosa (n = 79) and adenoma (n = 62) tissues from these patients when available. As control tissue, we used histologically normal biopsy material from control subjects who underwent endoscopy during 1987 -2004 for nonspecific abdominal complaints (n = 51), adenoma biopsy samples from patients diagnosed during 1988 -1995 and who did not develop colorectal cancer within 10 years of the adenoma diagnosis (n = 22), and resected colon mucosa from patients diagnosed during 1985 -2004 with various inflammatory bowel conditions (n = 33). The inflammatory bowel conditions in the latter group of control tissues included Crohn disease (n = 1), colitis ulcerosa (n = 5), nonspecific inflammation (n = 9), and diverticulitis (n = 18). Control tissues were excluded if the patient had been diagnosed with colorectal cancer in the past or during follow-up. We excluded patients with and without colorectal cancer who had been diagnosed with additional cancers (excluding nonmelanoma skin cancer). Characteristics of the study populations are shown in Supplementary
CONTEXT AND CAVEATS
Prior knowledge
Identification of tumor suppressor gene promoter hypermethylation in fecal DNA is a promising strategy for noninvasive detection of colorectal cancer. N-Myc downstream-regulated gene 4 ( NDRG4 ) is a potential tumor suppressor in colorectal cancer.
Study design
NDRG4 promoter methylation and expression were analyzed in human colorectal cancer cell lines, noncancerous colon mucosa, and colorectal cancer tissue. NDRG4 tumor suppressor functions were examined in colorectal cancer cells. NDRG4 promoter methylation was examined as a potential biomarker in stool from colorectal cancer patients and subjects without colorectal cancer.
Contribution
NDRG4 promoter methylation was prevalent in colorectal cancers compared with noncancerous colon mucosa. NDRG4 mRNA and protein expression were decreased in colorectal cancer tissue compared with noncancerous colon mucosa. NDRG4 overexpression in human colorectal cancer cells inhibited colony formation and cell proliferation and invasion in vitro. A methylation-specific polymerase chain reaction assay for NDRG4 promoter methylation identified colorectal cancer when it was present (sensitivity) in 53% of colorectal cancer cases and correctly categorized a subject as cancer free (specificity) 100% of the time.
Implications
NDRG4 is a candidate tumor suppressor gene in colorectal cancer. NDRG4 promoter methylation is a potential biomarker for the noninvasive detection of colorectal cancer in stool samples.
Limitations
Not all stool samples from colorectal cancer patients were collected before colonoscopy as was done for the control subjects. The colorectal cancer patients were older than the subjects without colorectal cancer.
From the Editors Figure 1 , Supplementary Table 1, and Supplementary Table 2 (available online). Numbers of samples in the results section may differ from those indicated in the table because not all samples could be amplified by using methylation-specific PCR. The second population-based series of formalin-fi xed, paraffi nembedded colorectal cancers (n = 184) was randomly selected from the prospective Netherlands Cohort Study on Diet and Cancer (NLCS), which has been described in detail elsewhere ( 17 , 18 ) . The 184 patients from whom this series of colorectal cancers were obtained were similar to the complete group of eligible colorectal cancer patients in the NLCS with respect to age at diagnosis, sex, TNM stage ( 19 ) , and tumor location. This study was approved by the Medical Ethical Committee (MEC) of the Maastricht University Medical Center.
DNA Isolation
A 5-µ m section of each tissue block was stained with hematoxylin and eosin and reviewed by the study pathologist (A. P. de Bruïne). Five sections (20 µ m thick) were deparaffinized and subjected to genomic DNA extraction by using a Puregene DNA isolation kit (Qiagen, Hilden, Germany) according to the manufacturer ' s instructions.
Collection and Preparation of Fecal DNA
Stool samples were obtained from healthy colonoscopy-negative control subjects older than 50 years who underwent colonoscopy screening for colorectal cancer within the framework of a workplace-based community colorectal cancer study at the Maastricht University Medical Center. Stool samples and colorectal cancer tissues were collected from colonoscopy-confirmed colorectal cancer case patients who were diagnosed with all stages of colorectal cancer at the VU University Medical Center in Amsterdam. Two independent sets of noncancerous control subjects and colorectal cancer patients were included in this study: a training set consisting of 28 colorectal cancer patients and 45 noncancerous control subjects and a test set consisting of 47 colorectal cancer patients and 30 noncancerous control subjects. Series characteristics are shown in Supplementary Table 3 (available online) . The MEC of the Maastricht University Medical Center and the Dutch Health Council approved this study. Written informed consent was obtained from all subjects who provided stool samples. All control stool samples from both sets of patients, one colorectal cancer stool sample from the training set, and three colorectal cancer stool samples from the test set were collected within 2 weeks before colonic purgation and colonoscopy. Twenty-seven colorectal cancer stool samples from the training and 44 colorectal cancer stool samples from the test set were collected 5 -7 days after colonoscopy and before resection of the tumor.
Stool stabilization buffer was added to the stool sample by the subject immediately after defecation (EXACT Sciences, Marlborough, MA), and stool samples were processed within 48 hours after defecation. For recovery of human DNA, whole-stool samples were homogenized in a sevenfold excess volume of stool stabilization buffer and aliquoted in 32-mL portions that contained the equivalent of 4 g of stool each. Single aliquots were centrifuged at 13 100 g for 2 minutes, and the supernatants were incubated with RNase A (80 U/mL) for 60 minutes at 37°C. Total DNA was precipitated by using 2.2 mL of 3 M sodium acetate (pH 5.2) and 22 mL of 100% isopropanol, centrifuged at 4500 g for 5 minutes, and resuspended in 4 mL of 1 mM EDTA, 0.01 M Tris -HCl (pH 7.4).
Half of each DNA sample was stored at Ϫ 20°C, and the other half was purifi ed as follows. Stool lysis buffer (1.5 mL; ASL buffer; Qiagen) and an InhibitEX tablet (Qiagen) were added to 2 mL of the DNA sample, and the mixture was centrifuged at 4500 g for 5 minutes. After centrifugation, the supernatant was pipetted into a new tube and the pellet was discarded. We added 2 mL of the supernatant to 150 µ L of proteinase K (>600 mAU/mL; Qiagen), then added 2.4 mL of lysis buffer (AL buffer; Qiagen), and incubated the mixture for 10 minutes at 70°C. We next added 2 mL of ethanol to the incubated sample, and the mixture was loaded onto a QiAamp Midi column (Qiagen), which was centrifuged at 1850 g for 3 minutes. The column was washed sequentially with 2 mL of wash buffer 1 (AW1 buffer; Qiagen) and 2 mL of wash buffer 2 (AW2 buffer; Qiagen), with centrifugation at 4500 g for 15 minutes. We added 200 µ L of elution buffer (buffer AE; Qiagen) onto the membrane of the column, and the column was incubated at room temperature for 5 minutes. Finally, the column was centrifuged at 4500 g for 2 minutes. The eluted fecal DNA (2 µ g) was subjected to bisulfi te modifi cation in 96-well plates (Tecan, Männedorf, Switzerland) by using an EZ-96 DNA Methylation kit (Zymo Research Co, Orange, CA) according to the manufacturer's protocol. Bisulfi te-treated fecal DNA was concentrated by using a DNA Clean & Concentrator kit (Zymo Research Co). NDRG4 promoter methylation in fecal DNA was analyzed by quantitative methylationspecifi c PCR as described below.
Sodium Bisulfite Conversion, Sequencing, and Quantitative Methylation-Specific PCR Sodium bisulfite modification, which converts unmethylated cytosine residues to uracil residues, was carried out on 500 ng genomic DNA isolated from the tissue sections and colorectal cancer cell lines (HT29, SW48, CaCo2, Colo205, RKO, LS174T, HCT116, and SW480) with the use of an EZ DNA methylation kit (Zymo Research Co) according to the manufacturer's instructions. NDRG4 methylation-specific PCR analysis was performed on bisulfitemodified DNA as described in detail elsewhere ( 20 , 21 ) .
For sequencing, bisulfi te-modifi ed DNA was amplifi ed using methylation-specifi c primers (shown in Supplementary Table 3, available online) and a PCR profi le consisting of an initial denaturation at 95°C for 5 minutes; followed by 35 cycles of 30 seconds at 95°C, 30 seconds at 60°C, and 1 minute at 72°C; and a fi nal extension at 72°C for 5 minutes. PCR products were cloned by using a TOPO-TA cloning kit (Invitrogen, Breda, the Netherlands), and six independent bacterial clones were sequenced by using an automated DNA sequencer (Applied Biosystems, Foster City, CA). Quantitative methylation-specifi c PCR was performed by using a 7900HT realtime PCR system (Applied Biosystems) as follows: 2.4 µ L bisulfi temodifi ed DNA was added to a PCR mix containing buffer [16.6 mM (NH 4 ) 2 SO 4 , 67 mM Tris, 6.7 mM MgCl 2 , 10 mM ␤ -mercaptoethanol], dATP, dCTP, dGTP, and dTTP (each at 5 mM), forward primer (6 ng/ µ L), reverse primer (18 ng/ µ L), a single-stranded oligonucleotide hybridization probe (0.16 µ M), bovine serum albumin (BSA; 0.1 µ g), and Jumpstart Taq polymerase (0.4 U; SigmaAldrich). ␤ -Actin was used as a reference gene for normalization.
The PCR program was as follows: 5 minutes at 95°C; followed by 45 cycles of 30 seconds at 95°C, 30 seconds at 57°C, and 30 seconds at 72°C; followed by 5 minutes at 72°C. Serially diluted plasmids (20 -2 000 000 copies) containing the target sequence were amplifi ed to generate a standard curve against which the unknown samples are quantifi ed by interpolation of their PCR cycle number (Ct value) to the corresponding plasmid copy. Primer sequences are provided in Supplementary Table 3 (available online) . Samples were handled and analyzed in a blinded fashion during storage, DNA isolation, and PCR analysis. One quantitative methylation-specifi c PCR experiment was performed for each independent set of patients .
Cell Culture and Transfections
Human colorectal cancer cell lines (HT29, SW48, CaCo2, Colo205, RKO, LS174T, HCT116, and SW480; all from LGC, Teddington, UK) were cultured in Dulbecco's modified Eagle medium (DMEM) (Invitrogen) supplemented with 10% heatinactivated fetal calf serum (FCS; HyClone, Etten-Leur, the Netherlands). To investigate the effect of reexpression of NDRG4 , RKO and HCT116 cells were treated for 3 days with 1 µ M DAC (Sigma). The full-length NDRG4 cDNA (Origene, Rockville, MD) was subcloned into a pCMV6-Neo vector (Origene) to create pCMV6-NDRG4. HCT116 cells were transfected with pCMV6-NDRG4 or empty vector (pCMV6) by use of a Nucleofector Kit V (Amaxa Biosystems, Gaithersburg, MD) according to the manufacturer's guidelines. RKO cells were transfected with pCMV6-NDRG4 or pCMV6 by using Lipofectamine 2000 Reagent (Invitrogen) according to the manufacturer's protocol. Transfected HCT116 and RKO cells were grown for 10 days in medium containing G418 (at 400 µ g/mL for HCT116 and 1 mg/mL for RKO; Invitrogen) to select for cells that were stably transfected with the pCMV6-based plasmids.
Quantitative Real-Time PCR Total RNA was isolated from colorectal cancer cell lines and tissues from patients and control subjects by using an RNeasy Mini kit (Qiagen) according to the manufacturer's instructions and treated with RNase-free DNAse (Qiagen) to remove contaminating genomic DNA. cDNA was synthesized from 1 µ g of the DNAse-treated RNA by using an Iscript cDNA synthesis kit (Bio-Rad, Hercules, CA). Quantitative real-time PCR to quantify NDRG4 mRNA levels was performed by using SYBR Green PCR master mix (Applied Biosystems, Nieuwekerk a/d IJssel, the Netherlands) as described previously ( 22 ) . Cyclophilin A was used as a reference gene for normalization. Primers used are listed in Supplementary Table 3 (available online) .
Immunohistochemistry
Immunohistochemistry was performed on formalin-fixed, paraffin-embedded tissue sections (5 µ m thick). Sections were deparaffinized in xylene, rehydrated, and incubated with 0.3% hydrogen peroxide in methanol for 30 minutes. The sections were incubated with Tris-buffered saline (TBS), 20% FCS, and 0.1% Tween to block nonspecific antibody binding, followed by incubation with the anti-NDRG4 monoclonal antibody (Abnova Corporation, Taipei City, Taiwan) diluted 1:6000 in TBS with 0.1% Tween and 0.5% BSA. Sections were incubated with a horseradish peroxidase -conjugated secondary antibody against mouse, rabbit, and rat IgGs (Poly-HRP GAM/R/R IgG) (Immunovision Technologies, Burlingame, CA), and bound antibody was visualized by using 3,3-diaminobenzidine substrate as a chromogen (Dako, Glostrup, Denmark) followed by hematoxylin counterstaining.
Colony Formation Assay
Colorectal cancer RKO and HCT116 cells were transfected in sixwell plates (1 × 10 6 cells per well) with pCMV6 or pCMV6-NDRG4 as described above. The next day, the cells were diluted 1:20 and G418 (at 1 mg/mL for RKO 400 µ g/mL for HCT116) was added to the medium to select for cells in which the plasmids had stably integrated into genomic DNA. After 14 days of selection, colonies were stained by using Giemsa's azur eosin methylene blue solution (Merck, Darmstadt, Germany) and counted. Colony formation was assessed in four different experiments (two replicate wells per experiment).
In Vitro Cell Proliferation, Migration, and Invasion Assays HCT116 cells were seeded onto 96-well plates (5000 cells per well), and cell numbers were counted 24, 48, 72, and 96 hours later (three wells per time point). In addition, after 96 hours of incubation, the cultures were pulse labeled for 6 hours with [methyl- Cell migration and invasion assays were performed using matrigel-coated (invasion assay) or uncoated (migration assay) 24-well transwell plates (8-µ m pore size) (BD Biosciences, Franklin Lakes, NJ). Briefl y, 2 × 10 5 HCT116 cells in DMEM containing 1% FCS were seeded into the upper chamber of each well, and DMEM containing 20% FCS was placed in the lower chamber. After 48 hours of incubation, the transwells were disassembled and the membranes that separated the upper and lower chamber of each transwell were fi xed with methanol and stained with 1% toluidine blue in 1% borax and the cells on the lower surface of the membrane were counted with the use of a light microscope. Transwell experiments were assessed in three different experiments (two replicate wells per experiment).
Statistical Analysis
For comparison between NDRG4 methylation frequencies in normal, adenoma, and carcinoma tissues from colorectal cancer patients and normal and adenoma tissues from control subjects without colorectal cancer, we used logistic regression ( Table 1 ) . Because we observed statistically significant differences in age between the cancer patients and control subjects (analyzed using one-way analysis of variance [ANOVA] ) and in tumor location among the cancer patients (analyzed using Pearson 2 test) (Supplementary Table 1 , available online), logistic regression analyses were adjusted for age and location. To compare the prevalence of NDRG4 promoter methylation in colorectal cancer tissue in relation to clinicopathological features, the Pearson (age at diagnoses) was used ( Table 2 ). In the hospital-based series, noncancerous control tissues, adenoma tissues, and carcinoma tissues were obtained from the same patients. These paired samples were analyzed by using the McNemar test to compare NDRG4 methylation frequencies in carcinoma, adenoma, and normal tissues from colorectal cancer patients ( Table 3 ) . Where appropriate, the Bonferroni method was used to correct for multiple comparisons.
For quantitative methylation-specifi c PCR analysis, we used receiver operating characteristic (ROC) curve analysis and the area under the curve (AUC) to determine the best cutoff value for highest sensitivity and specifi city. NDRG4 promoter methylation was considered positive if the methylation value was greater than the cutoff. Because age differences were expected between cancer patients and control subjects, an ROC curve and generalized linear (ROC-GLM) regression model was used to assess the infl uence of the age difference on the accuracy of NDRG4 methylation as a biomarker for the detection of colorectal cancer.
Analysis of cell growth curves was performed by means of two-way ANOVA. The Student t test was used for analyses of [ 3 H]thymidine incorporation and anchorage-independent cell growth. The Mann -Whitney rank sum test was used to analyze data obtained in the colony formation, quantitative real-time PCR, migration, and invasion assays.
All P values are two-sided, and P values less than or equal to .05 were considered statistically signifi cant. Data analysis was done by using SPSS software (version 12.0.1; SPSS Inc., Chicago, IL)
Results
NDRG4 Promoter Methylation and mRNA Expression in Colorectal Cancer Cell Lines
The promoter region of the NDRG4 gene (National Center for Biotechnology Information [NCBI] accession number NM _020465) contains a dense CpG island located from nucleotides Ϫ 556 to +869 relative to the transcription start site ( Figure 1, A ) . To assay this region for potential methylation, we examined eight human colorectal cancer cell lines by methylation-specific PCR using primers located from Ϫ 250 to +10 relative to the transcription start site (primers are listed in Supplementary Table 3, available online). The NDRG4 promoter was methylated in all of the cell lines except SW480 ( Figure 1, B ) . To investigate the pattern of CpG island methylation in the NDRG4 promoter, we sequenced sodium bisulfite -modified genomic DNA isolated from HCT116 ( NDRG4 promoter methylation positive) and SW480 ( NDRG4 promoter methylation negative) cells. The promoter region spanning 39 CpG sites ( Ϫ 251 to +10) was PCR amplified using sodium bisulfite -modified genomic DNA as template. Bisulfite sequencing confirmed the methylation-specific PCR data in that HCT116 cells showed almost complete methylation, whereas SW480 cells showed almost no methylated CpGs ( Figure 1, C ) . To investigate whether promoter methylation was associated with inhibition of gene expression, we measured NDRG4 mRNA levels in HCT116 and RKO cells incubated with and without the DNA methylation inhibitor DAC. In both cell lines, endogenous NDRG4 mRNA levels were statistically significantly higher in DAC-treated cells than in untreated cells (DAC treated vs untreated, RKO cells: 4.4-fold increase, 95% confidence interval [CI] = 3.17-to 5.63-fold increase, P = .014; HCT116 cells: 1.7-fold increase, 95% CI = 0.93-to 2.47-fold increase, P = .037) ( Figure 1, D ) . * Methylation frequency is presented as the number of methylated samples divided by the total number of samples analyzed (%). P values (two-sided) were generated by using logistic regression with adjustment for age (continuous data) and tumor location (categories: proximal and distal location). P values are Bonferroni adjusted, and the cutoff for statistical significance is P = .017. CRC = colorectal cancer; NDRG4 = N-Myc downstream-regulated gene 4; MSP = methylation-specific polymerase chain reaction; p1 = methylation-specific primer pair 1; p2 = methylation-specific primer pair 2. 
Prevalence of NDRG4 Promoter Methylation in Primary Colorectal Adenomas and Carcinomas
Sequence analysis of sodium bisulfite -modified genomic DNA isolated from three pairs of primary colorectal cancer tissues and matched noncancerous colon normal mucosa showed dense methylation at the NDRG4 promoter (region Ϫ 251 to +10 relative to the transcription start site) in the colorectal cancers but almost no NDRG4 promoter methylation in matched normal colon mucosa ( Figure 2, A ) . It is interesting that the density of methylation was higher in the upstream region (ie, the region more 5 ′ relative to the transcription start site) of the NDRG4 CpG island than in the more downstream region ( Figure 2, A ) .
To examine the methylation status of the NDRG4 promoter in a large series of noncancerous colon mucosa, adenoma, and colorectal cancer tissues, we performed methylation-specifi c PCR with primer pair 1 (which is situated more to the 5 ′ -end of the NDRG4 promoter region, where the NDRG4 methylation density was higher compared with the upstream region; Figure 1, A ) . The frequency of NDRG4 promoter methylation was lower in the normal mucosa from the control subjects than in the colorectal cancer To confi rm the high prevalence of NDRG4 promoter methylation in colorectal cancer, we analyzed a second independent, populationbased series of colorectal cancers and observed that NDRG4 promoter methylation was present in 70% (128/184) of colorectal cancer patients (data not shown). In each of the two independent series of colorectal cancer patients, NDRG4 promoter methylation was not associated with age at diagnosis (mean age = 70 years), sex, proximal vs distal tumor location, or TNM stage ( Table 2 ) .
We next investigated whether NDRG4 promoter methylation changes during colorectal cancer progression by comparing the frequency of NDRG4 promoter methylation in samples of normal mucosa, adenoma, and colorectal cancer tissues ( Table 3 ). The NDRG4 promoter was more frequently methylated in colorectal carcinomas than in matched normal mucosa adjacent to the tumor (26/31 [84%] vs 5/31 [16%]; P < .001) ( Table 3 ). Adenoma samples from colorectal cancer patients also had a statistically signifi cantly higher NDRG4 promoter methylation frequency than normal colon samples (22/36 [61%] vs 5/36 [14%]; P < .001) ( Table 3 ) . Finally, the frequency of NDRG4 promoter methylation was higher in colorectal carcinomas than in matched adenoma samples, but the difference was not statistically signifi cant (26/32 [81%] vs 20/32 [63%]; P = .54) ( Table 3 ) .
Heterogeneity of NDRG4 Promoter Methylation
As described above, we observed that the density of methylation was higher in the upstream region of the NDRG4 promoter CpG island than in the more downstream region. We therefore used methylation-specific PCR primer pair 2, which amplifies a region downstream of primer pair 1 ( Figure 1, A ) , to investigate this region for NDRG4 promoter methylation. The sensitivity for colorectal cancers (the proportion of people with disease who have a positive test result) decreased from 86% with primer pair 1 to 71% with primer pair 2, whereas the specificity (the proportion of people without disease with a negative test result) increased from 96% to 100%. Intriguingly, using primer pair 2, we found a statistically significant difference in the frequency of NDRG4 promoter methylation between matched adenomas and carcinomas from the colorectal cancer patients (13/33 [39%] vs 25/33 [76%]; P = .012), which was not observed using primer pair 1 ( Table 3 ) .
NDRG4 mRNA and Protein Expression in Colorectal Cancer
We next examined whether methylation of the CpG island in the NDRG4 promoter is associated with gene silencing by investigating NDRG4 mRNA expression in colorectal cancer tissue and matched normal colon mucosa from three colorectal cancer patients. In each of the three pairs of tissue, the NDRG4 mRNA level in the colorectal cancer was statistically significantly lower than that in the matched normal colon mucosa ( P = .037 for all three matched pairs). Compared with the NDRG4 mRNA level in the matched normal tissue (set at 100%), the expression of NDRG4 in tumor 1, 2, and 3 was 3% (95% CI = Ϫ 3% to 8%), 31% (95% CI = 9% to 58%), and 1.5% (95% CI = 1.3% to 1.7%), respectively ( Figure 2, B ) .
Next, we performed immunohistochemistry to investigate NDRG4 protein expression in a matched pair of normal colonic mucosa and colorectal cancer tissue from a colorectal cancer patient. In normal colon mucosa, NDRG4 expression was predominantly in basolateral membranes within colonocytes and increased in intensity near the mucosal surface ( Figure 2 , C , panel a). The matched colorectal cancer tissue showed heterogeneous cytoplasmatic staining with the anti-NDRG4 antibody. Similar results were observed in matched pairs of tissues from other colorectal cancer patients (data not shown). In most tumors, less than 50% of the tumor area showed weak to focally strong NDRG4 expression ( Figure 2, C , panels b and c) .
To investigate the association between NDRG4 promoter methylation and NDRG4 expression, we performed immunohistochemical analysis of NDRG4 protein expression on tissues from 80 colorectal cancer patients of the population-based series. We observed no association between NDRG4 promoter methylation and NDRG4 expression, suggesting that an alternative mechanism might account for NDRG4 inactivation in colorectal cancer. Therefore, we analyzed macrodissected colorectal cancer tissue and matched normal tissues from 86 colorectal cancer case patients of the population-based series for loss of heterozygosity. In addition, 12 primary colorectal cancers and the colorectal cancer cell lines HCT116 and SW480 were analyzed for NDRG4 mutations. We observed loss of heterozygosity in 27 (31%) of 86 colorectal cancers. No inactivating mutations within the coding region of the NDRG4 gene were detected in the 12 colorectal carcinomas. However, we found one novel nonsynonymous mutation in the SW480 cell line (40662A → AG Ile65Val [an A-to-G substitution at nucleotide 4066, resulting in an isoleucine-to-valine substitution at amino acid 65]). In addition, two previously reported single-nucleotide polymorphisms (SNPs) were detected among the 12 colorectal cancers. One SNP was observed in one of the 12 colorectal cancers (43760G → GG Val224Val [a G-to-GG substitution at nucleotide 43760, no difference in amino acid]); NCBI SNP database [dbSNP] accession number rs17821543). The second SNP was observed in nine of the 12 colorectal cancers (48311A → AG Ser354Ser [an A-to-AG substitution at nucleotide 43760, no difference in amino acid]; NCBI dbSNP accession number rs42945).
Effect of NDRG4 Overexpression in Colorectal Cancer Cell Lines
To examine whether NDRG4 acts as a tumor suppressor in colorectal cancer cells, we characterized HCT116 and RKO cells that were transfected with an expression vector harboring the full-length NDRG4 cDNA or empty vector (control). NDRG4 transfectants (pools of stably transfected cells) showed increased expression of NDRG4 mRNA compared with control cells transfected with empty vector (HCT116 52%, P = .005; RKO 69%, P = .037). In addition, NDRG4 protein expression was increased in the NDRG4 transfectants compared with the control cells transfected with empty vector (data not shown). Compared with control transfectants, transfection with NDRG4 statistically significantly reduced the number of G418-resistant colonies (HCT116: 77% reduction [95% CI = 66% to 90% reduction], P = .014; RKO: 69% reduction [95% CI = 61% to 76% reduction], P = .014) ( Figure 3, C and D ) and statistically significantly decreased cell proliferation as measured by [ 3 H] thymidine activity (HCT116: 40% reduction [95% CI = 27% to 44% reduction], P < .001) ( Figure 3 , E and F ). NDRG4 transfectants displayed reduced invasion through matrigel-coated transwell membranes compared with control transfectants (HCT116: 48% reduction [95% CI = 31% to 64% reduction], P < .001) ( Figure 3, G ) . However, transfection of NDRG4 had no effect on HCT116 cell migration compared with controltransfected cells ( Figure 3, H ) . Taken together, these data suggest that NDRG4 exhibits tumor-suppressive effects in human colorectal cancer cells.
Sensitivity and Specificity of NDRG4 Promoter Methylation in Fecal DNA for the Detection of Colorectal Cancer
The high prevalence of NDRG4 promoter methylation in colorectal cancer and the absence of methylation in normal colon mucosa suggested that NDRG4 promoter methylation could be a sensitive and specific biomarker for the noninvasive detection of colorectal cancer in human stool. Therefore, we developed a quantitative molecular beacon -based methylation-specific PCR assay that used a primer pair situated between methylationspecific PCR primer pair 1 and methylation-specific PCR primer pair 2 and fecal DNA isolated from stool ( Figure 1, A ) . We first examined NDRG4 promoter methylation as a biomarker for colorectal cancer in a training set comprising 28 colorectal cancer patients and 45 healthy control subjects. We used the data from the training set to construct an ROC curve with an AUC of 0.77 (95% CI = 0.66 to 0.86) ( Figure 4 ) . Using a cutoff level of 1.22 copies, which gave the highest sensitivity and specificity for the detection of colorectal cancer, we detected NDRG4 promoter methylation in 17 of the 28 colorectal cancer patients, yielding a sensitivity of 61% (95% CI = 43% to 79%) for the detection of colorectal cancer. Three (7%) of the 45 healthy control subjects tested positive for NDRG4 methylation, which resulted in a specificity of the assay of 93% (95% CI = 90% to 97%). To test the accuracy of the NDRG4 promoter methylation cutoff generated from the training set, we assayed NDRG4 promoter methylation by using quantitative methylation-specific PCR in an independent series of 47 colorectal cancer patients and 30 healthy control subjects, which were handled in a blinded fashion. Using the previously determined cutoff level of 1.22 methylated copies, we found that 25 of the 47 colorectal cancer patients tested positive for NDRG4 methylation, resulting in a sensitivity of 53% (95% CI = 39% to 67%), and that none of the 30 control subjects tested positive, yielding a specificity of 100% (95% CI = 86% to 100%).
Because the mean age of the colorectal cancer patients differed statistically signifi cantly from that of the control subjects in the training and test set (Supplementary Table 4 , available online), we used an ROC-GLM regression model in the training set to assess the accuracy of NDRG4 promoter methylation for the detection of colorectal cancer after adjustment for age. This analysis indicated that age did not statistically signifi cantly infl uence the accuracy ( P = .89, ROC-GLM regression model) ( 23 ) . These data indicate that detection of NDRG4 promoter methylation in fecal DNA can be used as a novel biomarker for detection of colorectal cancer.
Discussion
Here we describe the identification and validation of NDRG4 promoter methylation, a novel, sensitive, and specific marker for the detection of colorectal cancer. We found a statistically significant difference in the frequency of NDRG4 promoter methylation between colorectal cancer and normal colon mucosa. Adding inflamed mucosa, which often shows promoter CpG island methylation ( 24 ) , to the normal colon mucosa control group only slightly reduced the specificity of NDRG4 promoter methylation from 96% to 94%, indicating that NDRG4 promoter methylation is not associated with inflammation. Although most CpG island promotermethylated genes are frequently associated with a proximal tumor location ( 25 ) , NDRG4 promoter methylation is present in both distal colorectal cancers [often associated with chromosomal instability ( 26 ) ] and proximal colorectal cancers (often associated with microsatellite instability). This finding makes NDRG4 promoter methylation a promising marker to detect chromosomal-instable as well as microsatellite-instable colorectal cancers. We also found that DNA methylation density was higher in the upstream region of the NDRG4 promoter than in the downstream region. Therefore, we used two different pairs of methylation-specific PCR primers that amplify overlapping fragments in the CpG island to detect NDRG4 promoter methylation. Using primer pair 1 (the one most 5 ′ to the transcription start site) to detect NDRG4 promoter methylation resulted in a sensitivity for colorectal cancer of 86% and for adenoma of 66% and a specificity of 96%. Using primer pair 2, the sensitivity for colorectal cancers and adenomas decreased to 71% and 41%, respectively, whereas the specificity increased to 100%. This finding suggests that NDRG4 promoter hypermethylation initially occurs at the 5 ′ -end of the NDRG4 CpG island and spreads toward the transcription start site before ultimately shutting down NDRG4 mRNA expression, as has also been observed in the promoter for RUNX3 ( 27 , 28 ) .
In addition, we found a statistically signifi cantly lower methylation frequency in adenoma tissue compared with carcinoma tissue when we used primer pair 2 to detect NDRG4 promoter methylation. This fi nding suggests that DNA methylation in the promoter of NDRG4 may spread toward the transcription start site during cancer progression.
To our knowledge, expression of NDRG4 has been documented only in brain and heart tissue by Northern blotting. Here we show that NDRG4 mRNA and protein is expressed in normal colon tissue and that expression of both is decreased in colorectal cancer. However, we found no statistically signifi cant association between NDRG4 promoter methylation and NDRG4 expression. We and others ( 29 ) also found no evidence for mutational inactivation of NDRG4. However, we observed loss of heterozygosity of the NDRG4 locus at chromosome 16q in 31% of the colorectal cancers analyzed. Frequent loss of heterozygosity at 16q was previously observed in a wide variety of solid tumor types, including breast ( 30 ), liver ( 31 , 32 ) , prostate ( 33 ) , ovarian ( 34 ) , and Wilms tumors ( 35 ) , but, to our knowledge, has not been described in colorectal cancer. These fi ndings suggest that promoter methylation and loss of heterozygosity contribute to the altered expression of NDRG4 in colorectal cancer.
We also provide evidence that NDRG4 has tumor suppressor activities in colorectal cancer. Overexpression of NDRG4 in the colorectal cancer HCT116 cells inhibited colony formation and cell proliferation and invasion in vitro, suggesting that NDRG4 is a tumor suppressor gene in colorectal cancer. The ability of the NDRG4 -transfected cells to migrate in vitro was identical to that of control cells, which was also observed for NDRG1 ( 4 ) .
To investigate the potential utility of NDRG4 promoter methylation as a noninvasive biomarker test to identify individuals who should undergo colonoscopy because they are at increased risk for colorectal cancer, we analyzed fecal DNA of colorectal cancer patients and control subjects. We showed that detection of NDRG4 promoter methylation in fecal DNA was both sensitive and specifi c at identifying colorectal cancer patients in two independent series of case patients and control subjects. The prevalence of NDRG4 promoter methylation in colorectal cancer tissue (86% and 70% in two independent series) suggests that the use of optimal protocols for the isolation of fecal DNA could, in theory, yield a stool NDRG4 quantitative methylation-specifi c PCR test with an even higher sensitivity. Methyl-binding domain protein columns to capture methylated DNA, which have been shown to markedly increase sensitivity without decreasing specifi city ( 36 ) , may be useful in this respect. Several studies have provided proof of principle for the detection of promoter CpG island hypermethylation of colorectal adenoma or colorectal cancer -derived DNA in stool ( 37 -43 ) and blood ( 44 -49 ) . Compared with other gene promoter methylation markers described thus far ( 37 -39 , 44 -48 ) , NDRG4 promoter methylation performs well as a novel single marker. Combining NDRG4 promoter methylation with other DNA markers could improve its sensitivity and specifi city for the detection of colorectal cancer, as has been observed for other methylation markers ( 50 , 51 ) . In addition, the specifi city of NDRG4 promoter methylation for gastrointestinal adenocarcinomas makes it a specifi c biomarker for detecting gastrointestinal cancers in stool and blood.
The stool study presented here should be considered a pilot study that has specifi c limitations. Not all stool samples from colorectal cancer patients were collected before colonoscopy as was done for the control subjects. It is therefore possible, albeit very unlikely, that colonoscopy could have introduced artifacts in the observed methylation prevalence. In addition, the age of the colorectal cancer patients and control subjects differed statistically signifi cantly, which raises the question of whether the detected NDRG4 promoter methylation is associated with age. However, this possibility is highly unlikely because neither data from the two independent colorectal cancer series nor the ROC-GLM regression analysis of the stool samples showed that NDRG4 promoter methylation was associated with age. Nevertheless, the stool data should be validated in a large prospective screening study for colorectal cancer, as should NDRG4 promoter methylation be combined with other methylation markers to enhance the sensitivity and/or specifi city.
In conclusion, to our knowledge, this is the fi rst study to describe a tumor suppressor role for NDRG4 in cancer. Our data indicate that NDRG4 promoter methylation is potentially useful as a sensitive and specifi c noninvasive preselection modality for identifying individuals at risk for colorectal cancer for whom colonoscopy is recommended.
